AGLE - Aeglea BioTherapeutics, Inc.
| Previous Close | 8.87 |
| Open | 8.96 |
| Bid | 1.00 x 1100 |
| Ask | 8.90 x 1800 |
| Day's Range | 8.32 - 8.96 |
| 52 Week Range | 5.99 - 10.49 |
| Volume | 93,574 |
| Avg. Volume | 143,815 |
| Market Cap | 245.527M |
| Beta (3Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.00 |
- Simply Wall St.
Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price?
Anyone researching Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) might want to consider the historical volatility of the...
- GlobeNewswire
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today presented positive 20-dose data on 14 patients from the Company’s completed Phase 1/2 trial and ongoing Phase 2 open-label extension (OLE) trial for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) at the 2019 Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM). “We continue to see a transformative impact of pegzilarginase on plasma arginine control with accompanying improvements in important disease manifestations,” said Anthony G. Quinn, M.B. Ch.B., Ph.D., president and chief executive officer of Aeglea.
- GlobeNewswire
Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
AUSTIN, Texas, Aug. 29, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide.
- GlobeNewswire
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from.
- Benzinga
The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
- GlobeNewswire
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to the Company’s lead investigational therapy, pegzilarginase, for the treatment of Arginase 1 Deficiency (ARG1-D), a rare progressive disease presenting in early childhood that results in severe complications and early mortality. "The emerging clinical data demonstrating favorable effects of pegzilarginase treatment on both plasma arginine levels and important disease manifestations has led to the FDA’s designation of pegzilarginase as a breakthrough therapy," said Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea.
- Simply Wall St.
Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register?
If you want to know who really controls Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), then you'll have to look at the...
- GuruFocus.com
Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of Shares
President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 31,905 shares of AGLE on 06/14/2019 at an average price of $6.16 a share.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE)
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- GlobeNewswire
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced the dosing of the first patient in the Company’s Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) clinical trial. The pivotal trial is intended to further evaluate the efficacy and safety of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D), a progressive disease presenting in early childhood that results in severe complications and early mortality.
- GlobeNewswire
Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences
AUSTIN, Texas, May 30, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide.
- TheStreet.com
These 3 Biotech Stocks Are Attracting Insider Buying
Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.
- GuruFocus.com
Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of Shares
President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 26,592 shares of AGLE on 05/22/2019 at an average price of $6.77 a share.
- Associated Press
Aeglea: 1Q Earnings Snapshot
On a per-share basis, the Austin, Texas-based company said it had a loss of 59 cents. Aeglea shares have dropped 6.5% since the beginning of the year. The stock has declined 28% in the last 12 months. ...
- GlobeNewswire
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of.
- Simply Wall St.
Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look...
- Zacks
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
- GlobeNewswire
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today presented new positive Phase 1/2 data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) in Bellevue, Washington. The oral presentation was delivered by Dr. George Diaz, M.D., Ph.D., Division Chief of Medical Genetics in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mt. Sinai, New York, NY, and a Principal Investigator on the pegzilarginase Phase 1/2 trial.
- GlobeNewswire
Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
AUSTIN, Texas, April 01, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme.
- GlobeNewswire
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
AUSTIN, Texas, March 28, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme.
- Thomson Reuters StreetEvents
Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 Aeglea Bio Therapeutics Inc Earnings Call
Motley FoolAeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call Transcript
AGLE earnings call for the period ending December 31, 2018.
- GlobeNewswire
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with.
- Simply Wall St.
The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On
If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right individual stocks, you could makeRead More...
- GlobeNewswire
Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
AUSTIN, Texas, Feb. 28, 2019 -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme.
